Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

Nosocomial Infection Clinical Trial

Official title:

Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03413293
• Other study ID #: NBFCIIHCP
• Status: Not yet recruiting
• Start date: June 2018
• Est. completion date: August 2019

Study information

• Verified date: February 2018
• Source: Assiut University
• Contact: Nariman zaghluol bakhiet, postgraduate
• Phone: 01005546130
• Email: narimandoctor[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hospital acquired chest Infections are common complications in hospitalized cirrhotic patients. Infectious complications are the most common cause of mortality in cirrhotic patients with bronchopneumonia early antibiotic treatment at the base of culture and sensitivity is an optimal therapeutic approach in cirrhotics with nosocomial pneumonia Intensive care unit acquired pneumonia is the leading infection in critically ill patients and a major cause of morbidity and mortality despite recent major advances in antimicrobial therapy, supportive care, and the use of a broad range of preventive measures

Description:

Aim of the work

1. To estimate the frequency and risk factors of nosocomial chest infections in cirrhotic patients .

2. To determine the causative pathogens of nosocomial chest infections in patients with cirrhosis including fungal infections in order to establish our local empirical antimicrobial protocol.

3. To define the impact of nosocomial chest infections on survival of our patients.

4. To develop an effective and continuous surveillance program and infection control measures to reduce the burden of these infections as well as morbidity , mortality , hospital stay ,hospital cost and to achieve quality of care .

5. To motivate pharmaceutical companies to create a new umbrella coverage of antimicrobials through the ongoing knowledge of the changes in microbial resistance pattern inside hospitals

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: August 2019
• Est. primary completion date: May 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• All cirrhotic patients , decompensated , child pug score B or C ,may have Hepatocellular carcinoma , other comorbidities may present as (Diabetius mellitus , Hypertension , Heart disease and renal impairment ) , both sex and with clinical suspicion of chest infections acquired after 48 hours of admission

Exclusion Criteria:

• Patients have any chronic chest disease

• Patients have severe immunosuppression (neutropenia after chemotherapy or hematopoietic transplant, drug-induced immunosuppression in solid-organ transplant or cytotoxic therapy, and HIV-related disorders.

Related Conditions & MeSH terms

• Communicable Diseases
• Cross Infection
• Infection
• Nosocomial Infection

Intervention

Diagnostic Test:
• Diagnosis of bacterial infections
Cultures

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

Di Pasquale M, Esperatti M, Crisafulli E, Ferrer M, Bassi GL, Rinaudo M, Escorsell A, Fernandez J, Mas A, Blasi F, Torres A. Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. Intensive Care Med. 2013 Oct;39(10):1776-84. doi: 10.1007/s00134-013-3025-6. Epub 2013 Aug 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of nosocomial infection in patients with liver cirrhosis	nosocomial infection is one of predictors of bad outcome in liver cirrhosis	baseline